Abstract
The recombinant human growth hormone has been used for about 40 years and is administered as a single daily dose. Long-acting growth hormones are developed to enhance therapy adherence and reduce therapy load. Somatrogone, the first and only weekly growth hormone in our country, has been well tolerated by patients, and no serious adverse events have occurred. Somatrogon obtained a license in our country on March 9, 2023, and was reimbursed on May 17, 2024. The recommended dosage is once a week, 0.66 mg/kg/dose on the same day of the week, available for use in the forms of 24 mg and 60 mg. Somatrogon is expected to provide an advantage in ease of weekly administration and treatment load and improve treatment compliance. It is also essential to closely monitor the long-term studies and the treatment’s effectiveness, safety, and adherence.
Keywords:
Growth hormone, weekly treatment, somatrogone, adherence
References
1
Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl. 1986;325:1-9.
2
Eslami P, Sayarifard F, Safdari R, Shahmoradi L, Karbasi Z. Global perspective on pediatric growth hormone registries: a systematic review. J Pediatr Endocrinol Metab. 2022;35:709-26.
3
Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, Ibáñez L, Carlsson M, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab. 2022;107:3287-301.
4
Aydın BK, Aycan Z, Sıklar Z, Berberoğlu M, Ocal G, Cetinkaya S, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract. 2014;20:46-51.
5
Eren E, Çetinkaya S, Denkboy Ongen Y, Tercan U, Darcan Ş, Turan H, et al. Adherence to growth hormone treatment in children during COVID-19 pandemic. J Clin Res Pediatr Endocrinol. 2024.
6
Çetinkaya S, Eren E, Erdoğan F, Darendeliler F. Long-acting growth hormone therapy, rational and future aspects. J Clin Res Pediatr Endocrinol. 2024.
7
https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya Available from: 15/04/2021 https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla Available from: 02/03/2022 https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma Available from: 04/02/2022
8
Ngenla kısa ürün bilgisi - https://www.titck.gov.tr/kubkt0kb_d585eb51-7702-45c4-8614-88cca34ab822.pdf
9
Calo D, Hart G, Hoffman M, Yagev LI, Tzur Y, Binder L, et al. Enhancing the longevity and in vivo potency of therapeutic proteins: the power of CTP. Precision Medicine. 2015;2:e989
10
Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa V, et al. In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone. Mol Pharm. 2016;13:631-9.
11
Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, et al. Long-acting c-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD Children. J Clin Endocrinol Metab. 2017;102:1578-87.
12
Fisher DM, Rosenfeld RG, Jaron-Mendelson M, Amitzi L, Koren R, Hart G. Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children. Horm Res Paediatr. 2017;87:324-32.
13
Lamb YN. Somatrogon: first approval. Drugs. 2022;82:227-34.
14
Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, et al. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab. 2023;36:261-9.
15
Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107:e2717-28.
16
Ranke MB, Dowie J. KIGS and KIMS as tools for evidence-based medicine. Horm Res. 1999;51 Suppl 1:83-6.
17
Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievskiy OA, Mauras N, et al. OR21-04 Long-term efficacy and safety of once-weekly somatrogon in pediatric subjects with growth hormone deficiency: results from up to 8 years of somatrogon treatment. J Endocr Soc. 2023;7:bvad114.1522.
